Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
- 1 May 2018
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 25 (3) , e349-e356
Abstract
Background: Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer diagnoses each year. SCLC is characterized by a rapid doubling time, early metastatic spread, and an unfavorable prognosis overall. Areas of Uncertainty: Most patients with SCLC will respond to initial treatment; however, the majority will experience a disease recurrence and response to second-line therapies is poor. Immune checkpoint inhibitors may be an option given the success in other diseases. Data Sources: A literature search was conducted using Medline (1946–July week 1, 2017) and Embase (1996–2017 week 28) with the search terms small cell lung cancer combined with nivolumab or ipilimumab or pembrolizumab or atezolizumab or tremelimumab or durvalumab. Five clinical trials, including extended follow-up for 2, that evaluated immune checkpoint inhibitors in limited stage or extensive stage SCLC were included. Results: In 2 phase 2 trials, ipilimumab was added to upfront chemotherapy. In both trials, an improvement in progression-free survival was seen. Toxicity, when combined with a platinum and etoposide, was significant. In a confirmatory phase 3 trial, ipilimumab did not prolong overall survival when added to first-line chemotherapy. Overall, response rates were similar between the placebo and ipilimumab groups. A phase 1/2 trial evaluated nivolumab alone or in combination with ipilimumab in recurrent SCLC. Results revealed that nivolumab monotherapy and the combination of nivolumab and ipilimumab were relatively safe and had antitumor activity. Pembrolizumab has been evaluated in a multicohort, phase 1b trial. Preliminary data showed a durable response in the second-line setting. Conclusion: Given the lack of overall survival data and significant toxicity associated with the combination of ipilimumab with first-line chemotherapy, this treatment is not a reasonable option at this time. Nivolumab alone or in combination with ipilimumab is a valid option for recurrent SCLC.Keywords
This publication has 23 references indexed in Scilit:
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based ChemotherapyThe Oncologist, 2016
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians GuidelineJournal of Clinical Oncology, 2015
- Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center ExperienceJournal of Cancer, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Treatment of Small Cell Lung CancerChest, 2013
- Small-cell lung cancerThe Lancet, 2011
- New Advances in the Second-Line Treatment of Small Cell Lung CancerThe Oncologist, 2009
- Management of Recurrent Small Cell Lung CancerJournal of the National Comprehensive Cancer Network, 2008
- Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?The Oncologist, 2007
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999